Menopauza u kobiety ze stwardnieniem rozsianym Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2024
Słowa kluczowe:
stwardnienie rozsiane, menopauza, hormonalna terapia zastępcza
##plugins.themes.bootstrap3.article.main##
Abstrakt
Stwardnienie rozsiane to choroba występująca przede wszystkim u kobiet, a hormony płciowe odgrywają istotną rolę nie tylko w okresie rozrodczym kobiety, lecz także w okresie menopauzy i w okresie pomenopauzalnym. Zmiany hormonalne związane z menopauzą mają wpływ na zmianę przebiegu stwardnienia rozsianego (brak aktywności oraz obserwowanej progresji klinicznej). Objawy związane z menopauzą mogą się nakładać lub nasilać objawy neurologiczne. Stosowanie hormonalnej terapii zastępczej nie wpływa negatywnie na przebieg choroby i może łagodzić objawy menopauzy.
##plugins.themes.bootstrap3.article.details##
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Salpietro V, Polizzi A, Recca G et al. The role of puberty and adolescence in the pathobiology of pediatric multiple sclerosis. Multiple Scler Demyelinating Disorders. 2018; 3: 1-10.
2. Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol. 2021; 17: 676-88. https://doi.org/10.1038/s41582-021-00556-y .
3. Rommer PS, Ellenberger D, Hellwig K et al. Relapsing and progressive MS: the sex-specific perspective. Ther Adv Neurol Disord. 2020; 13: 1756286420956495.
4. Ribbons KA, McElduff P, Boz C et al. Male sex is independently associated with faster disability accumulation in relapse onset MS but not in primary progressive MS. PLoS ONE. 2015; 10(6): e0122686.
5. Ysrraelit MC, Correale J. Impact of sex hormones on immune function and multiple sclerosis development. Immunology. 2019; 156(1): 9-22. http://doi.org/10.1111/imm.13004.
6. Confavreux C, Hutchinson M, Hours MM et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple Sclerosis Group. N Engl J Med. 1998; 339: 285-91.
7. Bridge F, Butzkueven H, Van der Walt A et al. The impact of menopause on multiple sclerosis. Autoimmun Rev. 2023; 22(8): 103363. http://doi.org/10.1016/j.autrev.2023.103363.
8. MacKenzie-Graham AJ, Rinek GA, Avedisian A et al. Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis. J Neurosci Res. 2012; 90(7): 1310-23. http://doi.org/10.1002/jnr.2301924.
9. Baroncini D, Annovazzi PO, De Rossi N et al. Impact of natural menopause on multiple sclerosis: a multicentre study. J Neurol Neurosurg Psychiatry. 2019; 90: 1201-6.
10. Hall JE. Endocrinology of the Menopause. Endocrinol Metab Clin North Am. 2015; 44(3): 485-96. http://doi.org/10.1016/j.ecl.2015.05.010.
11. Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. Am J Med. 2005; 118: 124-30. http://doi.org/10.1016/j.amjmed.2005.09.046.
12. Lorefice L, D’Alterio MN, Firinu D et al. Impact of Menopause in Patients with Multiple Sclerosis: Current Perspectives. Int J Womens Health. 2023; 15: 103-9. http://doi.org/10.2147/IJWH.S334719.
13. Davis SR. Understanding weight gain at menopause. Climacteric. 2012; 15: 419-29. http://doi.org/10.3109/13697137.2012.707385.
14. Pillay CO, Manyonda I. The surgical menopause. Best Pract Res Clin Obstet Gynaecol. 2022; 81: 111-8. http://doi.org/10.1016/j.bpobgyn.2022.03.001.
15. Hsu S, Bove R. Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data. Curr Neurol Neurosci Rep. 2024; 24(1): 1-15. http://doi.org/10.1007/s11910-023-01326-7.
16. Goetzl EJ, Huang MC, Kon J et al. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev. 2021; 71: 101422.
17. Pawelec G. Immunosenescence and cancer. Biogerontology. 2017 ;18(4): 717-21. http://doi.org/10.1007/s10522-017-9682-z .
18. Campisi J, Robert L. Cell senescence: role in aging and age-related diseases. Aging. 2014; 39: 45-61.
19. Gameiro CM, Romão F, Castelo-Branco C. Menopause and aging: changes in the immune system – a review. Maturitas. 2010; 67(4): 316-20.
20. Bove R, Healy BC, Musallam A et al. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016; 22(7): 935-43. http://doi.org/10.1177/1352458515606211.
21. Silverman HE, Bostrom A, Nylander AN et al. Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis. Neurology. 2025; 104(2): e210228. http://doi.org/10.1212/WNL.0000000000210228.
22. Bove R, Healy BC, Secor E et al. Patients report worse MS symptoms after menopause: findings from an online cohort. Mult Scler Relat Disord. 2015; 4(1): 18-24. http://doi.org/10.1016/j.msard.2014.11.009.
23. Ladeira F, Salavisa M, Caetano A et al. The influence of menopause in multiple sclerosis course: a longitudinal cohort study. Eur Neurol. 2018; 80(3-4): 223-7. http://doi.org/10.1159/000496374.
24. Giordano A, Giliberti A, Clarelli F et al. Sex hormone-related factors and the risk of PIRA in women with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2025; 13: jnnp-2024-335547. http://doi.org/10.1136/jnnp-2024-335547.
25. Tansavatdi K, McClain B, Herrington DM. The effects of smoking on estradiol metabolism. Minerva Ginecol. 2004; 56(1): 105-14.
26. Lorefice L, Frau J, Coghe G et al. Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: a case- control MRI study. Mult Scler Relat Disord. 2019; 27: 74-78. http://doi.org/10.1016/j.msard.2018.10.011.
27. Bove R, Vaughan T, Chitnis T et al. Women’s experiences of menopause in an online MS cohort: A case series. Mult Scler Relat Disord. 2016; 9: 56-9. http://doi.org/10.1016/j.msard.2016.06.015.
28. Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014; 20(5): 520-6. http://doi.org/10.1177/1352458513519181.
29. Christianson MS, Mensah VA, Shen W. Multiple sclerosis at menopause: Potential neuroprotective effects of estrogen. Maturitas. 2015; 80(2): 133-9. http://doi.org/10.1016/j.maturitas.2014.11.013.
30. Meyer CE, Smith AW, Padilla-Requerey AA et al. A. Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol. Lab Invest. 2023; 103(8): 100189. http://doi.org/10.1016/j.labinv.2023.100189.
31. Hodis HN, Mack WJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: It is about time and timing. Cancer J. 2022; 28(3): 208-23.
32. Davis SR, Baber RJ. Treating menopause – MHT and beyond. Nat Rev Endocrinol. 2022; 18(8): 490-502. http://doi.org/10.1038/s41574-022-00685-4.
33. Voskuhl RR, Wang H, Wu TC et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: A randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016; 15(1): 35-46.
34. Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; 310(13): 1353-68. http://doi.org/10.1001/jama.2013.278040.
35. Bove R, Secor E, Chibnik LB et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014; 82(3): 222-9. http://doi.org/10.1212/WNL.0000000000000033.
36. Vural P, Akgul C, Canbaz M. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res. 2006; 54(4): 298-302. http://doi.org/10.1016/j.phrs.2006.06.006.
2. Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol. 2021; 17: 676-88. https://doi.org/10.1038/s41582-021-00556-y .
3. Rommer PS, Ellenberger D, Hellwig K et al. Relapsing and progressive MS: the sex-specific perspective. Ther Adv Neurol Disord. 2020; 13: 1756286420956495.
4. Ribbons KA, McElduff P, Boz C et al. Male sex is independently associated with faster disability accumulation in relapse onset MS but not in primary progressive MS. PLoS ONE. 2015; 10(6): e0122686.
5. Ysrraelit MC, Correale J. Impact of sex hormones on immune function and multiple sclerosis development. Immunology. 2019; 156(1): 9-22. http://doi.org/10.1111/imm.13004.
6. Confavreux C, Hutchinson M, Hours MM et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple Sclerosis Group. N Engl J Med. 1998; 339: 285-91.
7. Bridge F, Butzkueven H, Van der Walt A et al. The impact of menopause on multiple sclerosis. Autoimmun Rev. 2023; 22(8): 103363. http://doi.org/10.1016/j.autrev.2023.103363.
8. MacKenzie-Graham AJ, Rinek GA, Avedisian A et al. Estrogen treatment prevents gray matter atrophy in experimental autoimmune encephalomyelitis. J Neurosci Res. 2012; 90(7): 1310-23. http://doi.org/10.1002/jnr.2301924.
9. Baroncini D, Annovazzi PO, De Rossi N et al. Impact of natural menopause on multiple sclerosis: a multicentre study. J Neurol Neurosurg Psychiatry. 2019; 90: 1201-6.
10. Hall JE. Endocrinology of the Menopause. Endocrinol Metab Clin North Am. 2015; 44(3): 485-96. http://doi.org/10.1016/j.ecl.2015.05.010.
11. Freedman RR. Hot flashes: behavioral treatments, mechanisms, and relation to sleep. Am J Med. 2005; 118: 124-30. http://doi.org/10.1016/j.amjmed.2005.09.046.
12. Lorefice L, D’Alterio MN, Firinu D et al. Impact of Menopause in Patients with Multiple Sclerosis: Current Perspectives. Int J Womens Health. 2023; 15: 103-9. http://doi.org/10.2147/IJWH.S334719.
13. Davis SR. Understanding weight gain at menopause. Climacteric. 2012; 15: 419-29. http://doi.org/10.3109/13697137.2012.707385.
14. Pillay CO, Manyonda I. The surgical menopause. Best Pract Res Clin Obstet Gynaecol. 2022; 81: 111-8. http://doi.org/10.1016/j.bpobgyn.2022.03.001.
15. Hsu S, Bove R. Hormonal Therapies in Multiple Sclerosis: a Review of Clinical Data. Curr Neurol Neurosci Rep. 2024; 24(1): 1-15. http://doi.org/10.1007/s11910-023-01326-7.
16. Goetzl EJ, Huang MC, Kon J et al. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? Ageing Res Rev. 2021; 71: 101422.
17. Pawelec G. Immunosenescence and cancer. Biogerontology. 2017 ;18(4): 717-21. http://doi.org/10.1007/s10522-017-9682-z .
18. Campisi J, Robert L. Cell senescence: role in aging and age-related diseases. Aging. 2014; 39: 45-61.
19. Gameiro CM, Romão F, Castelo-Branco C. Menopause and aging: changes in the immune system – a review. Maturitas. 2010; 67(4): 316-20.
20. Bove R, Healy BC, Musallam A et al. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016; 22(7): 935-43. http://doi.org/10.1177/1352458515606211.
21. Silverman HE, Bostrom A, Nylander AN et al. Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis. Neurology. 2025; 104(2): e210228. http://doi.org/10.1212/WNL.0000000000210228.
22. Bove R, Healy BC, Secor E et al. Patients report worse MS symptoms after menopause: findings from an online cohort. Mult Scler Relat Disord. 2015; 4(1): 18-24. http://doi.org/10.1016/j.msard.2014.11.009.
23. Ladeira F, Salavisa M, Caetano A et al. The influence of menopause in multiple sclerosis course: a longitudinal cohort study. Eur Neurol. 2018; 80(3-4): 223-7. http://doi.org/10.1159/000496374.
24. Giordano A, Giliberti A, Clarelli F et al. Sex hormone-related factors and the risk of PIRA in women with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2025; 13: jnnp-2024-335547. http://doi.org/10.1136/jnnp-2024-335547.
25. Tansavatdi K, McClain B, Herrington DM. The effects of smoking on estradiol metabolism. Minerva Ginecol. 2004; 56(1): 105-14.
26. Lorefice L, Frau J, Coghe G et al. Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: a case- control MRI study. Mult Scler Relat Disord. 2019; 27: 74-78. http://doi.org/10.1016/j.msard.2018.10.011.
27. Bove R, Vaughan T, Chitnis T et al. Women’s experiences of menopause in an online MS cohort: A case series. Mult Scler Relat Disord. 2016; 9: 56-9. http://doi.org/10.1016/j.msard.2016.06.015.
28. Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014; 20(5): 520-6. http://doi.org/10.1177/1352458513519181.
29. Christianson MS, Mensah VA, Shen W. Multiple sclerosis at menopause: Potential neuroprotective effects of estrogen. Maturitas. 2015; 80(2): 133-9. http://doi.org/10.1016/j.maturitas.2014.11.013.
30. Meyer CE, Smith AW, Padilla-Requerey AA et al. A. Neuroprotection in Cerebral Cortex Induced by the Pregnancy Hormone Estriol. Lab Invest. 2023; 103(8): 100189. http://doi.org/10.1016/j.labinv.2023.100189.
31. Hodis HN, Mack WJ. Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: It is about time and timing. Cancer J. 2022; 28(3): 208-23.
32. Davis SR, Baber RJ. Treating menopause – MHT and beyond. Nat Rev Endocrinol. 2022; 18(8): 490-502. http://doi.org/10.1038/s41574-022-00685-4.
33. Voskuhl RR, Wang H, Wu TC et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: A randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2016; 15(1): 35-46.
34. Manson JE, Chlebowski RT, Stefanick ML et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013; 310(13): 1353-68. http://doi.org/10.1001/jama.2013.278040.
35. Bove R, Secor E, Chibnik LB et al. Age at surgical menopause influences cognitive decline and Alzheimer pathology in older women. Neurology. 2014; 82(3): 222-9. http://doi.org/10.1212/WNL.0000000000000033.
36. Vural P, Akgul C, Canbaz M. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res. 2006; 54(4): 298-302. http://doi.org/10.1016/j.phrs.2006.06.006.